CD4 and breast carcinoma: We first compared Treg frequencies by flow cytometry in PB and BM of healthy individuals (PB n = 7 and BM n = 8) and 50 breast cancer patients using CD25, FoxP3, and CD4 as Treg markers (Fig. 1a–c).